(2025)
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Lancet Microbe
[Epub ahead of print]
Dr. Florian Kloß
AlumniPublications
(2025)
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.
Nat Commun 16(1),
826.
(2024)
In vitro antibacterial activity of microbial natural products against bacterial pathogens of veterinary and zoonotic relevance.
Antibiotics (Basel) 13(2),
135.
(2024)
Modulation of the Meisenheimer complex metabolism of nitro-benzothiazinones by targeted C-6 substitution.
Commun Chem 7(1),
153.
(2024)
Deazaflavin metabolite produced by endosymbiotic bacteria controls fungal host reproduction.
ISME J 18(1),
wrae074.
(2024)
Replacement of the essential nitro group by electrophilic warheads towards nitro-free antimycobacterial benzothiazinones.
Eur J Med Chem 279,
116849.
(2023)
Prenylated isoflavanones with antimicrobial potential from the root bark of Dalbergia melanoxylon.
Metabolites 13(6),
678.
(2023)
Pharmacokinetics and efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside granulomas in the Guinea pig model.
Antimicrob Agents Chemother 67(4),
e0143822.
(2023)
Whole cell hydride Meisenheimer complex biotransformation guided optimization of antimycobacterial benzothiazinones.
Eur J Med Chem 264,
116023.
(2023)
Design and synthesis of benzofuran- and naphthalene-fused thiazinones as antimycobacterial agents.
Arch Pharm (Weinheim) 356(11),
e2300356.